China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901 intravitreal implant, co-filed with EyePoint Pharmaceuticals, Inc (NASDAQ: EYPT), has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended to be assessed as a potential treatment for pathological myopia with choroidal neovascularization (pmCNV).
EYP-1901: A Promising Treatment for Pathological Angiogenic Disease
EYP-1901 is a combination product consisting of vorolanib, a multi-target tyrosine kinase VEGFR/PDGFR inhibitor with a novel chemical structure, specifically designed for the treatment of pathological angiogenic diseases. It is combined with Durasert, an approved intravitreous drug delivery system. Betta Pharmaceuticals expanded its agreement with EyePoint in May 2022, securing development and commercialization rights to the drug in Greater China, including Hong Kong, Macau, and Taiwan.
Ongoing Clinical Studies for EYP-1901 in the United States
In addition to the submission to the NMPA, EYP-1901 is also the subject of a Phase I DAVIO study for wet age-related macular degeneration (wAMD) and Phase II studies in both wAMD and non-proliferative diabetes retinopathy (NPDR) in the United States. These clinical studies further demonstrate the broad potential application of EYP-1901 in treating various ocular conditions.-Fineline Info & Tech
